PRX005 (also known as BMS-986446) is an investigational monoclonal antibody program for Alzheimer's disease under the Prothena-Bristol Myers Squibb collaboration. It targets tau within the microtubule-binding region and is in Phase 2 clinical evaluation in early Alzheimer's disease. The program is not approved by regulatory authorities.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
